Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STI-6129 in Relapsed/Refractory AL Amyloidosis
NCT04316442Phase 2Unknown
- Sponsor
- Sorrento Therapeutics
- Start
- Apr 2021
- Primary completion
- Sep 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of STI-6129 in amyloid light chain amyloidosis, sponsored by Sorrento Therapeutics. Primary endpoint: Safety and tolerability of STI-6129 up to 14 months. Status: unknown.
02
Drugs
STI-6129
03
Conditions
amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT04316442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04316442.